Predictive Oncology Inc. POAI Cash Flow

Predictive oncology inc. (POAI)
CashFlow / TTM

Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Net loss
-	-	-	-11,619	-	-7,765	-6,250	-6,421	-6,003	-5,610	-5,673	-5,691	-6,526	-8,056	-8,117	-6,741	-4,790	-4,892	-4,891	-5,442	-6,833	-6,622	-9,482	-8,921	-9,406	-8,969	-7,850	-8,810	-7,422	-8,672	-6,471	-4,722	-4,486	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on equity method investment
-439	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
704	525	365	168	147	123	76	71	71	73	76	79	82	83	81	79	78	76	76	73	63	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Vesting expense
2,250	2,328	2,308	1,162	1,124	956	627	1,937	2,298	2,160	2,248	714	165	698	617	837	871	0	0	0	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Issuance of common stock in cashless warrant exercise
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	148	156	142	1	1	2	2	2	3	0	0	0
Equity instruments issued for management and consulting
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-260	-164	112	20	2,691	2,643	3,700	3,958	2,138	2,099	830	2,336	2,007	1,998	1,937	0	0	0
Equity instruments issued for management and consulting
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	283	234	239	281	2,109	3,667	3,919	4,139	2,233	740	507	0	0	0
Capital contributions resulting from waivers of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Amortization of debt discount
2,023	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	219	378	466	345	247	87	321	385	413	426	104	64	57	72	100	105	112	0	0	0
Gain on valuation of equity-linked instruments
-221	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on Sales of Equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	2	-2	-10	-17	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Gain (loss) from sale of marketable securities
-	-	-	-	-	-	-	-	-	4	6	6	4	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss (gain) on valuation of equity-linked financial instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11	15	80	149	157	72	25	15	-3	-286	-282	-155	-151	0	0	0
Changes in assets and liabilities:
Accounts receivable
-143	-74	-224	-68	95	146	270	173	98	46	21	15	0	30	7	-37	-19	-224	-133	26	-39	155	47	-32	57	43	69	77	-10	20	31	19	50	0	0	0
Inventories
-91	-97	52	16	-23	39	2	23	-7	-50	-49	-7	40	52	34	-44	-135	-78	-102	-90	245	214	252	250	-23	-33	11	49	47	134	96	91	97	0	0	0
Prepaid expense and other assets
29	-103	-192	-54	-139	22	86	48	141	33	-32	-10	-122	-50	18	91	81	64	53	-43	129	114	113	66	33	11	-30	-6	-2	-7	21	56	22	0	0	0
Accounts payable
365	978	998	245	305	334	108	107	-79	-573	-693	-712	-430	-490	-1,723	-1,672	-1,544	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Notes payable to shareholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,021	547	429	36	214	346	421	418	196	95	71	0	0	0
Accrued expenses
1,285	1,716	719	742	493	-817	-805	-831	-870	-119	-93	666	791	-181	-2,120	-2,103	-2,415	-875	998	1,353	1,594	1,832	1,946	664	776	458	548	878	1,039	188	179	128	92	0	0	0
Deferred revenue
17	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	5	9	9	2	-24	-3	-66	0	24	3	2	-64	0	0	54	69	5	5	15	0	0	0	0	-	-	-	-
Net cash used in operating activities
-8,732	-7,155	-6,225	-5,642	-5,287	-5,392	-5,496	-4,997	-4,459	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,376	-1,617	-1,664	-1,781	0	0	0
Cash flow from investing activities:
Net cash used in operating activities:
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10,057	-9,069	-7,487	-4,866	-1,638	-1,624	-3,371	-3,661	-3,679	-4,667	-3,855	0	0	0	-	-	-	-	-	-	-	-
Purchase of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of marketable securities
-	-	-	-	-	-	-	-	-	576	856	856	571	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of certificates of deposit
-	-	-	-	-	-	-	-	3,084	2,694	2,693	2,693	1,100	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Redemption of certificates of deposit
-	-	-	-	244	1,714	3,184	3,184	2,940	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Advances on notes receivable
975	1,973	2,056	1,712	1,123	1,077	1,780	1,780	1,737	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of fixed assets
-	-	-	-	177	171	136	50	45	50	52	42	32	57	51	49	32	-1	29	29	101	215	225	235	162	49	9	0	0	0	0	0	0	0	0	0
Transfer of fixed assets to inventory
-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition of intangibles
20	26	35	33	54	48	36	34	10	11	8	10	11	12	25	21	28	24	12	13	19	20	19	67	53	52	48	0	0	0	0	0	0	0	0	0
Net cash used in investing activities:
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,627	-1,871	-60	-22	-41	-42	-121	-236	-244	-302	-216	0	0	0	-	-	-	-	-	-	-	-
Net cash used in investing activities
-599	-1,606	-1,736	-1,880	-1,110	-73	740	828	-1,653	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0
Cash flow from financing activities:
Proceeds from debt issuance
2,690	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of debt
1,154	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants into common stock
-	-	-	-	650	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from long-term and convertible debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	647	1,542	1,822	1,698	1,456	678	528	647	684	525	525	0	0	0
Repayment of convertible debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	150	150	50	0	0	0	0	0	0
Principal payments on debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	300	300	0	0	0	0	0	6	8	12	16	0	0	0
Net proceeds from issuance of preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,055	2,055	2,055	2,055	0	0	0	0	-	-	-	-	-	-	-	-
Restricted cash in escrow
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Issuance of common stock
5,323	2,479	2,479	2,479	2,959	2,959	2,959	2,959	3,814	5,440	5,440	5,440	1,712	96	13,138	13,138	13,051	13,041	64	64	157	283	1,424	1,430	2,337	2,468	1,517	1,695	695	832	942	843	1,386	0	0	0
Net cash provided by financing activities
9,320	8,650	7,027	6,415	5,794	4,909	4,600	4,315	5,114	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,400	1,595	1,355	1,895	0	0	0
Net decrease in cash
-11	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,223	12,473	12,387	12,377	1,684	1,539	3,407	3,813	3,827	4,727	4,160	0	0	0	-	-	-	-	-	-	-	-
Net increase (decrease) in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-96	-242	88	226	101	350	-109	24	-22	-308	113	0	0	0
Non-cash transactions
Bridge loan conversion into common stock
378	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	415	0	0	0	-	-	-	-	-	-	-	-
Forbearance settlement bridge loan
503	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrants Issued
47	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion of preferred stock to common stock
-	-	-	-	6	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Equity method investment – Helomics
-	-	-	-	1,542	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issued for accrued interest/bonus
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,073	1,084	402	401	29	118	106	72	72	24	24	0	0	0
Conversion of accounts payable to convertible debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	89	0	0	0
Common stock issued to satisfy debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	483	884	964	609	480	80	2,140	2,296	2,318	2,328	188	756	817	857	857	113	50	0	0	0
Stock/warrant issued to satisfy accounts payable/Liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100	124	217	418	418	415	264	20	20	0	0	0